CAPR Class Alert: Capricor Therapeutics Securities Fraud Class Action to Recover Losses is Pending – Investors Notified to Contact BFA Law before September 28 Court Deadline

$CAPRPress releaseSep 11, 2026, 5:47 AM ETRead the release

Securities law firm Bleichmar Fonti & Auld LLP (BFA Law) announced a pending class action against Capricor Therapeutics and certain senior executives, alleging securities fraud under Exchange Act Sections 10(b) and 20(a). Investors have until September 28, 2026 to seek lead plaintiff status in Nkamga v. Capricor Therapeutics, Inc. et al., No.

Key figures

Adcom vote: 9-3 against efficacy support
Close july 24: $19.70
Close july 27: $7.00
Close july 29: $6.57
Close july 30: $4.19
July 27 stock drop pct: 64.5%
July 30 stock drop pct: 36%
Lead plaintiff deadline: September 28, 2026
July 27 stock drop usd per share: $12.70

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.